• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Oncotarget: Melatonin increases overall survival of prostate cancer patients

Bioengineer by Bioengineer
February 10, 2021
in Biology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

‘The results of the use of melatonin drugs in palliative treatment of patients with end-stage prostate cancer are shown’

IMAGE

Credit: Correspondence to – Vladimir N. Anisimov – [email protected]

Oncotarget recently published “Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment” which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019. Comprehensive statistical methods were used to analyze the overall survival rate of PCa patients treated with melatonin in various prognosis groups.

The overall survival rate of PCa patients with favorable and intermediate prognoses treated or not treated with melatonin was not statistically significantly different.

In the poor prognosis group, the median overall survival in patients taking the drug was 153.5 months versus 64.0 months in patients not using it.

In a multivariate analysis, melatonin administration proved to be an independent prognostic factor and reduced the risk of death of PCa patients by more than twice.

The multicomponent antitumor effect of melatonin is fully realized and clearly demonstrated in treatment of PCa patients with poor prognosis with a set of unfavorable factors of the tumor progression.

Dr. Vladimir N. Anisimov from The N.N. Petrov National Medical Research Center of Oncology said, “Melatonin is the main hormone of the pineal gland.“

Melatonin is most widely used in clinical practice to treat hormone-dependent tumors, and primarily in the combined treatment of breast cancer.

Some possible points of inhibition of tumor growth by melatonin included activation of T helper type 1; increased production of several cytokines; inhibition of angiogenesis; reduced expression of the VEGF receptors; activation of apoptosis in tumor cells; and a decrease in telomerase activity.

The results of the use of melatonin drugs in palliative treatment of patients with end-stage prostate cancer are shown.

“The results of the use of melatonin drugs in palliative treatment of patients with end-stage prostate cancer are shown”

Thus, the assessment of long-term results of wide clinical use of melatonin in the combined treatment of patients with prostate cancer of various risk groups is an urgent and relevant task.

The aim of the study was to improve the effectiveness of treatment of patients with prostate cancer by long-term use of melatonin drugs after a course of combined hormone-radiation treatment.

The Anisimov Research Team concluded in their Oncotarget Research Paper that “the results of our study are in agreement with the data on favorable antitumor effect melatonin treatment of patients with advanced cancer of various localization, mainly in the breast, uterus, colon, etc., .

Taking into consideration the optimistic conclusions obtained in our work, based on large clinical material, it is advisable to conduct prospective randomized studies with an assessment of survival rates in patients with PCa of various prognosis groups.”

###

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27757

Full text – https://www.oncotarget.com/article/27757/text/

Correspondence to – Vladimir N. Anisimov – [email protected]

Keywords –
prostate cancer,
overall survival,
poor prognosis,
melatonin

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

[email protected]
18009220957×105

Media Contact
Ryan James Jessup
[email protected]

Original Source

https://www.oncotarget.com/news/pr/melatonin-increases-overall-survival-of-prostate-cancer-patients/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27757

Tags: BiologyBreast CancerBusiness/EconomicscancerCarcinogensEducationMedicine/HealthPolicy/EthicsProstate Cancer
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

CK2–PRC2 Signal Drives Plant Cold Memory Epigenetics

August 2, 2025
blank

AI-Driven Protein Design Advances T-Cell Immunotherapy Breakthroughs

August 1, 2025

Melanthiaceae Genomes Reveal Giant Genome Evolution Secrets

August 1, 2025

“Shore Wars: New Study Tackles Oyster-Mangrove Conflicts to Boost Coastal Restoration”

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    36 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Gut γδ T17 Cells Drive Brain Inflammation via STING

Agent-Based Framework for Assessing Environmental Exposures

MARCO Drives Myeloid Suppressor Cell Differentiation, Immunity

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.